Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations

NCT03213691 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03213691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03213691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
October 30, 2017
Completion date
December 31, 2024
Enrollment
21 (actual)
Sites
110

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid neoplasm, ann arbor stage iii childhood non-hodgkin lymphoma, ann arbor stage iv childhood non-hodgkin lymphoma, recurrent childhood central nervous system neoplasm, recurrent childhood non-hodgkin lymphoma, recurrent malignant solid neoplasm, recurrent neuroblastoma, refractory malignant solid neoplasm, refractory neuroblastoma, refractory non-hodgkin lymphoma, refractory primary central nervous system neoplasm